Abstract:

A series of tests were conducted to investigate the drug efficacy and transdermal speed of ciclopirox olamine nanoemulsion in vitro and provide experimental basis for clinical application. Antifungal activity test of ciclopirox olamine in vitro was conducted by using the microdilution method and evaluation of its transdermal permeability was by utilizing modified Franz diffusion device. The results of antifungal activity test in vitro showed that the MIC to Candida albicans, Saccharomyces cerevisiae and Staphylococcus aureus was 0.125, 0.250 and 16.000 μg·mL^-1, respectively, which was better than results of ciclopirox olamine solution and bifonazole solution obviously. It is manifest that nanoemulsion as a kind of drug carrier can improve the antifungal activity of ciclopirox olamine. The results of transdermal permeability of ciclopirox olamine nanoemulsion in vitro test illuminate that the transdermal rate of ciclopirox olamine nanoemulsion and ones with 2%, 5% azone was (22.381±0.114), (134.573±0.012), (50.350±0.001) μg·cm^-2·h^-1, respectively, whereas the transdermal rate of ciclopirox with 20% ethanol solution was (10.891±0.062) μg·cm^-2·h^-1. It shows that ciclopirox olamine nanoemulsion enhances its percutaneous penetration (P<0.01) and it can further improve its transdermal ability in vitro when the azone was added (P<0.01). Overall, nanoemulsion as the carrier of ciclopirox olamine can improve its antifungal activity and transdermal speed, which provides a theoretical basis for clinical application of ciclopirox olamine nanoemulsion.